VASOVaso Corp

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

N/A

Location

New York, USA

Exchange

OTC

Website

https://vasocorporation.com

Summary

Vaso Corporation operates in the healthcare equipment and information technology industries in the United States and internationally.

Company Info

CEO

N/A

Location

New York, USA

Exchange

OTC

Website

https://vasocorporation.com

Summary

Vaso Corporation operates in the healthcare equipment and information technology industries in the United States and internationally.

AI Insights for VASO
6 min read

Quick Summary

Vaso Corporation is a small public company operating in healthcare equipment, healthcare-related sales services, and information technology. Its Equipment segment designs, manufactures, sells, and services proprietary medical devices, with a historical focus on noninvasive cardiovascular therapy and related systems. Its Professional Sales Service segment provides sales representation and support services in the healthcare market, serving hospitals, imaging centers, and medical providers that purchase complex medical equipment. Its IT segment provides technology services that support healthcare and enterprise customers, including implementation, managed services, and related support. The company’s main customers are healthcare providers, hospital systems, medical offices, and organizations that need specialized equipment, sales support, or healthcare-focused technology services.

Strengths

•

Vaso’s main strength is that it operates across multiple healthcare-related segments rather than depending on only one medical device product.

•

The company has exposure to medical equipment, professional sales services, and IT services, which can create revenue diversification and multiple customer touchpoints.

•

Its reported quarter shows positive net income and operating income, which is notable for a small OTC healthcare company.

•

The company’s low EV-to-revenue ratio and positive earnings yield may appeal to investors looking for undervalued or overlooked micro-cap healthcare names.

•

Vaso also operates in markets connected to cardiovascular care, hospital equipment, and healthcare technology, all of which have long-term demand drivers.

Key Risks

•

VASO carries substantial risks because it is a small OTC-traded company in a competitive healthcare market.

•

Its share price may be volatile due to limited liquidity, penny-stock sentiment, and sensitivity to small changes in buying or selling pressure.

•

Larger competitors can outspend Vaso on product development, clinical validation, sales coverage, regulatory work, and customer support.

•

The company may also face risks from hospital budget cycles, delayed capital purchases, reimbursement uncertainty, supply-chain pressure, and changes in healthcare procurement priorities.

What to Watch

During the most recent reported quarter in the provided data, Vaso showed positive operating results rather than a loss-making profile.
The company generated about $11.19 million in operating revenue and total revenue, indicating that its operating businesses continued to produce meaningful sales.
Gross profit was about $8.89 million, suggesting a high gross margin profile for the quarter based on the provided figures.
Operating income was about $974,000 and net income was about $544,000, which shows that the company remained profitable at both the operating and net levels.
No specific new product launch, dividend announcement, or upcoming earnings date was provided in the data.
The most notable strategic item in the recent news set was the previously announced plan to uplist from OTCQX to Nasdaq through a merger with Achari Ventures Holdings Corp.
I, although investors would need updated company filings to confirm timing, completion status, and final terms.

Price Drivers

•

VASO’s stock price is likely driven by a mix of profitability, revenue stability, liquidity, OTC-market sentiment, and expectations around strategic corporate actions.

•

The company reported operating revenue of about $11.19 million, gross profit of about $8.89 million, operating income of about $974,000, and net income of about $544,000 in the provided quarter, which supports the view that it is not merely a pre-revenue penny stock.

•

Valuation metrics such as a market capitalization of about $51.3 million, price-to-earnings ratio near 20.5, price-to-book ratio near 1.76, and EV-to-revenue near 0.146 may attract value-oriented investors if earnings and cash flow remain stable.

•

The stock may also react strongly to news about uplisting, merger plans, Nasdaq access, or improved investor visibility because it currently trades on the OTC market.

•

Broader healthcare equipment trends, cardiovascular-care demand, hospital capital spending, and penny-stock risk appetite can also influence price movement.

•

Liquidity is an additional driver because previous-day volume and average volume indicate that trading activity can vary, and lower-liquidity stocks can move sharply on modest order flow.

Recent News

•

Recent news highlighted Vaso’s plan to uplist from OTCQX to Nasdaq through a merger with Achari Ventures Holdings Corp.

•

The transaction was described as valuing Vaso at about $176 million, or about $10 per share, with shareholders expected to receive shares in the combined public company.

•

The combined company was expected to be led by CEO Jun Ma and to trade under the tickers VASO and VASOW, according to the news summary.

•

Vaso was also mentioned by InvestorPlace in lists of high-risk, high-upside penny stocks, where it was framed as a speculative name with potential but significant risk.

•

Other news in the dataset focused on broader healthcare, cardiac monitoring, and biotech themes rather than company-specific Vaso developments.

•

Investors should verify the latest status of the merger and uplisting through official filings because the supplied news references an expected closing timeline from 2024.

Market Trends

•

Vaso is affected by broader growth in cardiovascular care, healthcare equipment demand, and healthcare information technology.

•

The cardiac monitoring market is projected to grow meaningfully through 2030, supported by rising cardiovascular disease, demand for long-term monitoring, wearable devices, implantable devices, and AI-enabled analysis.

•

North America remains a leading healthcare technology market, which is relevant because Vaso is based in the United States and serves healthcare customers.

•

Hospitals and clinics are increasingly focused on connected care, data integration, patient monitoring, and efficient capital deployment, which can create both opportunities and competitive pressure.

•

Large companies such as Abbott, Medtronic, Philips, Boston Scientific, and Siemens Healthineers are shaping standards in these markets through innovation and scale.

•

At the same time, higher interest rates, hospital budget constraints, reimbursement scrutiny, and risk-off investor sentiment can reduce appetite for small healthcare equipment stocks.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on VASO

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

No more topics to show